Numerous clinical trials, including EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58, and VERTIS, have been conducted to evaluate the effectiveness of SGLT2 inhibitors in treating HF. The gene discussed is SLC5A2; the disease is hydrops fetalis.